Leebeek FWG - Search Results

1

von Willebrand Factor and Factor VIII Clearance in Perioperative Hemophilia A Patients.

van Moort I, Bukkems LH, Heijdra JM, Schutgens REG, Laros-van Gorkom BAP, Nieuwenhuizen L, van der Meer FJM, Fijnvandraat K, Ypma P, de Maat MPM, Leebeek FWG, Meijer K, Eikenboom J, Mathôt RAA, Cnossen MH; OPTI-CLOT Study Group. van Moort I, et al. Among authors: leebeek fwg. Thromb Haemost. 2020 Jul;120(7):1056-1065. doi: 10.1055/s-0040-1710591. Epub 2020 Jun 1. Thromb Haemost. 2020. PMID: 32480417 Clinical Trial.

2

Recombinant factor VIIa improves clot formation but not fibrolytic potential in patients with cirrhosis and during liver transplantation.

Lisman T, Leebeek FW, Meijer K, Van Der Meer J, Nieuwenhuis HK, De Groot PG. Lisman T, et al. Hepatology. 2002 Mar;35(3):616-21. doi: 10.1053/jhep.2002.31771. Hepatology. 2002. PMID: 11870375

3

Association between thrombin-activatable fibrinolysis inhibitor (TAFI) and clinical outcome in patients with unstable angina pectoris.

Brouwers GJ, Leebeek FW, Tanck MW, Wouter Jukema J, Kluft C, de Maat MP. Brouwers GJ, et al. Thromb Haemost. 2003 Jul;90(1):92-100. Thromb Haemost. 2003. PMID: 12876631

4

Genetic variability of von Willebrand factor and risk of coronary heart disease: the Rotterdam Study.

van der Meer IM, Brouwers GJ, Bulk S, Leebeek FW, van der Kuip DA, Hofman A, Witteman JC, Gómez García EB. van der Meer IM, et al. Br J Haematol. 2004 Feb;124(3):343-7. doi: 10.1046/j.1365-2141.2003.04776.x. Br J Haematol. 2004. PMID: 14717782 Free article.

5

In vitro studies, pharmacokinetic studies and clinical use of a high purity double virus inactivated FVIII/VWF concentrate (Immunate) in the treatment of von Willebrand disease.

Ver Elst KM, van Vliet HD, Kappers-Klunne MC, Leebeek FW. Ver Elst KM, et al. Thromb Haemost. 2004 Jul;92(1):67-74. doi: 10.1160/TH04-02-0107. Thromb Haemost. 2004. PMID: 15213847

6

Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity.

Lisman T, Bongers TN, Adelmeijer J, Janssen HL, de Maat MP, de Groot PG, Leebeek FW. Lisman T, et al. Hepatology. 2006 Jul;44(1):53-61. doi: 10.1002/hep.21231. Hepatology. 2006. PMID: 16799972

7

High von Willebrand factor levels increase the risk of first ischemic stroke: influence of ADAMTS13, inflammation, and genetic variability.

Bongers TN, de Maat MP, van Goor ML, Bhagwanbali V, van Vliet HH, Gómez García EB, Dippel DW, Leebeek FW. Bongers TN, et al. Stroke. 2006 Nov;37(11):2672-7. doi: 10.1161/01.STR.0000244767.39962.f7. Epub 2006 Sep 21. Stroke. 2006. PMID: 16990571

8

Variations in glycosylation of von Willebrand factor with O-linked sialylated T antigen are associated with its plasma levels.

van Schooten CJ, Denis CV, Lisman T, Eikenboom JC, Leebeek FW, Goudemand J, Fressinaud E, van den Berg HM, de Groot PG, Lenting PJ. van Schooten CJ, et al. Blood. 2007 Mar 15;109(6):2430-7. doi: 10.1182/blood-2006-06-032706. Epub 2006 Nov 7. Blood. 2007. PMID: 17090649 Free article.

9

Genetic variation in thrombin-activatable fibrinolysis inhibitor (TAFI) is associated with the risk of splanchnic vein thrombosis.

de Bruijne EL, Darwish Murad S, de Maat MP, Tanck MW, Haagsma EB, van Hoek B, Rosendaal FR, Janssen HL, Leebeek FW; Liver and Thrombosis Study Group. de Bruijne EL, et al. Thromb Haemost. 2007 Feb;97(2):181-5. Thromb Haemost. 2007. PMID: 17264944

10

Prothrombotic coagulation abnormalities in patients with paraprotein-producing B-cell disorders.

Auwerda JJ, Sonneveld P, de Maat MP, Leebeek FW. Auwerda JJ, et al. Clin Lymphoma Myeloma. 2007 Jul;7(7):462-6. doi: 10.3816/clm.2007.n.027. Clin Lymphoma Myeloma. 2007. PMID: 17875234

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

394 results

Search Page

Filters